v3.26.1
Segment Information - Schedule of Reportable Segment Revenue, Operating Expenses, and Net Loss (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Revenue:            
License and other revenue $ 350   $ 677   $ 3,350 $ 8,355
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] us-gaap:LicenseAndServiceMember   us-gaap:LicenseAndServiceMember   us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember
Total revenue $ 350   $ 677   $ 3,350 $ 8,355
Research and development expenses            
General and administrative expenses 14,691   13,627   25,718 32,366
Other segment expenses (income)            
Depreciation expense         864 2,210
Stock compensation expense         19,716 33,825
Interest income (7,115)   (7,105)   (12,467) (14,918)
Other (income) expense (2)   633   51 641
Reconciliation to consolidated net loss:            
Net loss (83,707) $ (73,291) (70,375) $ (77,065) (156,998) (147,440)
Operating Segments [Member]            
Revenue:            
License and other revenue $ 350   $ 677   $ 3,350 $ 8,355
Revenue from Contract with Customer, Product and Service [Extensible Enumeration] us-gaap:LicenseAndServiceMember   us-gaap:LicenseAndServiceMember   us-gaap:LicenseAndServiceMember us-gaap:LicenseAndServiceMember
Research and development expenses            
General and administrative expenses $ 11,306   $ 8,299   $ 18,423 $ 19,224
Other segment expenses (income)            
Depreciation expense 360   1,002   864 2,210
Interest income (7,115)   (7,105)   (12,467) (14,918)
Other (income) expense (2)   633   51 641
Segment net loss (83,707)   (70,375)   (156,998) (147,440)
Operating Segments [Member] | Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense            
Other segment expenses (income)            
Stock compensation expense 3,342   5,193   7,189 12,829
Operating Segments [Member] | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost            
Research and development expenses            
External costs for programs in clinical trials 48,329   20,488   89,712 44,161
External costs for platform technologies and preclinical programs 4,100   12,769   7,791 27,407
Employee related expenses 14,487   14,903   28,826 31,914
Other expenses 3,413   5,563   7,432 11,331
Other segment expenses (income)            
Stock compensation expense $ 5,837   $ 9,307   $ 12,527 $ 20,996